rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

John Townsend

CFO

Company insider

Files Form 4 as: CFO, Unicycive Therapeutics; Chief Accounting Officer, Guardion Health Sciences; Controller, Cerenome.

In numbers

Trades disclosed
17
Buys
0
Sells
0
Bought
$0
Sold
$0
Companies
3
Companies where not an officer
1
First trade
27 Jan 2011
Last trade
14 May 2026
Last filed
15 Jun 2026

Companies traded

Where they are an officer
UNCY Unicycive TherapeuticsOfficer · Biotechnology · last 14 May 20260 buys · 0 sells
CNSY CerenomeOfficer · Medical Devices · last 30 Jan 20150 buys · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
Guardion Health SciencesOther · last 30 Aug 20170 buys · 0 sells

Activity over time

Not enough dated trades to draw.

Every trade

TradedCompanyWhatAmount
14 May 2026filed 15 Jun 2026UNCY Unicycive Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—169,500 at $0.00filing
14 May 2026filed 15 Jun 2026UNCY Unicycive Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—169,500 at $0.00filing
14 May 2026filed 20 May 2026UNCY Unicycive Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—169,500 at $0.00filing
14 May 2026filed 20 May 2026UNCY Unicycive Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—169,500 at $0.00filing
28 Jul 2025filed 30 Jul 2025UNCY Unicycive Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—10,000 at $0.00filing
12 Aug 2024filed 14 Aug 2024UNCY Unicycive Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—40,256 at $0.00filing
15 Apr 2024filed 17 Apr 2024UNCY Unicycive Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—228,119 at $0.00filing
28 Aug 2023filed 30 Aug 2023UNCY Unicycive Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—570,329 at $0.00filing
21 Nov 2022filed 23 Nov 2022UNCY Unicycive Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—35,000 at $0.00filing
15 Jul 2021filed 26 Jul 2021UNCY Unicycive Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—18,605 at $0.00filing
30 Aug 2017filed 30 Aug 2017Guardion Health SciencesSEC FORM 4 Code A—100,000 at $0.00filing
31 Dec 2016filed 14 Feb 2017Guardion Health SciencesSEC FORM 4 Code A—5,000 at $0.00filing
31 Dec 2016filed 3 Jan 2017Guardion Health SciencesSEC FORM 4 Code A—5,000 at $0.00filing
30 Jan 2015filed 3 Feb 2015CNSY Cerenomeoption or derivative · Medical DevicesSEC FORM 4 Code A—10,000 at $0.00filing
21 Aug 2014filed 22 Aug 2014CNSY Cerenomeoption or derivative · Medical DevicesSEC FORM 4 Code A—15,000 at $0.00filing
11 Apr 2014filed 15 Apr 2014CNSY Cerenomeoption or derivative · Medical DevicesSEC FORM 4 Code A—25,000 at $0.00filing
27 Jan 2011filed 3 Feb 2011CNSY Cerenomeoption or derivative · Medical DevicesSEC FORM 4 Code A—15,000 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

No trade we could place in a sector.

Related people

Marc H. HedrickChief Executive Officer · Chief Executive Officer at Plus Therapeutics, filing Form 4 there in the last year
Ronald Asbury AndrewsDirector · Director at Plus Therapeutics, filing Form 4 there in the last year
Richard J. HawkinsDirector · Director at Plus Therapeutics, filing Form 4 there in the last year
Kyle GuseDirector · Director at Plus Therapeutics, filing Form 4 there in the last year
An van Es-JohanssonDirector · Director at Plus Therapeutics, filing Form 4 there in the last year